Mitoxantrone: an active agent in refractory non-Hodgkin's lymphomas.

Abstract

A phase II oriented study with mitoxantrone was undertaken in 31 patients with refractory non-Hodgkin's lymphomas (NHL); 30 patients had evaluable disease. The drug was administered through a 30-min intravenous infusion at the dose of 14 mg/m2 every 3 weeks. A minimum of two cycles were required to define treatment response. Twenty patients were previously treated with Adriamycin whose total dose was not exceeding 300 mg/m2. Complete response (CR) was documented in 9 patients, and partial response (PR), in 5 for a total response rate of 47% (14 of 30). Of 20 patients previously treated with Adriamycin, CR occurred in five and PR in two. The median time to progression was 3 months. Mitoxantrone was well tolerated, and no patient refused treatment. Mild leukopenia was evident in 10 patients and thrombocytopenia in 5 patients. In all cases, electrocardiograms (EKGs) was obtained before each treatment cycle. Systolic time intervals and left ventricular ejection fraction were repeated after 3 cycles and at the end of therapy. Laboratory tests failed to document any major cardiac abnormality. Mitoxantrone is an effective agent in refractory NHL and should be taken into consideration in the design of salvage regimens.

• Authors: E Bajetta, R Buzzoni, P Valagussa, G Bonadonna
• Journal: American journal of clinical oncology (Am J Clin Oncol) Vol. 11 Issue 2 Pg. 100-3 (Apr 1988) ISSN: 0277-3732 [Print] United States
• PMID: 3282421 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Doxorubicin
• Mitoxantrone

Topics

• Adult
• Aged
• Clinical Trials as Topic
• Doxorubicin (therapeutic use)
• Female
• Humans
• Infusions, Intravenous
• Lymphoma, Non-Hodgkin (drug therapy)
• Male
• Middle Aged
• Mitoxantrone (administration & dosage, adverse effects)